Liquidia to Present at Nano Manufacturing 2014 Conference

RESEARCH TRIANGLE PARK, NC – September 23, 2014

Presentation Highlights Strength of PRINT® Technology in Novel Product Development

Liquidia Technologies today announced it will present an overview of the unique capabilities of its PRINT® (Particle Replication In Non-Wetting Templates) technology at the Nano Manufacturing 2014 Conference being held September 24 at the Joint School of Nanoscience and Nanoengineering (JSNN) in Greensboro, NC. The inaugural Nano Manufacturing Conference was held in 2013 and brought together a broad representation of businesses, academia and government.

Derek Schorzman, Ph.D., Senior Principal Process Engineer at Liquidia, will give an oral presentation from 9:50 – 10:15 a.m. during the opening session of the conference. The title of the oral presentation is:

Nanoparticle Manufacturing Using the PRINT® Platform: Enabling Novel Products in the Life Sciences and Beyond

By leveraging precise fabrication techniques of the semiconductor industry, PRINT is the only technology in the world with the ability to rapidly design and manufacture precisely engineered particles of virtually any size, shape or chemistry, including small molecule active pharmaceutical ingredients (API), biologic APIs, and polymeric drug delivery systems (e.g. extended release formulations). This unique ability to precisely engineer micro- and nanoparticles enables scientists to explore new product frontiers that, until now, have otherwise been out of reach for the life sciences industry.

Liquidia is currently leveraging its PRINT technology to find innovative solutions that can address many of the challenges often encountered in vaccine and inhaled therapy development and manufacturing with the ultimate goal of creating safe and efficacious products. In addition, Liquidia licenses its PRINT technology and cGMP manufacturing capabilities to support proprietary programs advanced by collaborators, as well as the efforts of the company’s two recent spin-outs, Envisia Therapeutics and Lq3 Pharmaceuticals.


© 2017 Liquidia Technologies